<DOC>
	<DOCNO>NCT01155375</DOCNO>
	<brief_summary>To evaluate efficacy safety IV ferumoxytol compare oral iron treatment pediatric subject chronic kidney disease .</brief_summary>
	<brief_title>A Trial Ferumoxytol Treatment Iron Deficiency Anemia Pediatric Subjects With Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferrous fumarate</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<criteria>Key Inclusion Criteria include : 1 . Males females 6 month &lt; 18 year age 2 . CKD nondialysis subject dialysis dependent subject peritoneal dialysis stable hemodialysis prior screen 3 . Has IDA define : ) hemoglobin ≤12.0 g/dL b ) either TSAT ≤40 % ferritin &lt; 100 ng/mL 4 . Female subject childbearing potential sexually active must effective method birth control least 1 month prior screen agree remain birth control completion participation study Key Exclusion Criteria include : 1 . History allergy either oral intravenous ( IV ) iron 2 . Hemoglobin ≤7.0 g/dL 3 . Serum ferritin &gt; 600 ng/mL 4 . Female subject pregnant intend become pregnant , breastfeeding , within 3 month postpartum , positive serum pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Iron deficiency anemia</keyword>
	<keyword>Feraheme</keyword>
	<keyword>ferumoxytol</keyword>
	<keyword>CKD</keyword>
	<keyword>pediatric</keyword>
	<keyword>dialysis-dependent</keyword>
	<keyword>non-dialysis dependent</keyword>
	<keyword>The treatment iron deficiency anemia pediatric subject chronic kidney disease .</keyword>
</DOC>